Loading…
Scientific Protein Laboratories, LLC received a warning letter for manufacturing adulterated active pharmaceutical ingredients (APIs) that failed to meet Current Good Manufacturing Practice (CGMP) standards. During an April-May 2025 inspection of their Waunakee, Wisconsin facility, FDA investigators identified significant equipment deficiencies, specifically observing grooves and scratches on API contact surfaces of manufacturing tables used in pancrelipase production, which could contaminate the API with particulate matter and compromise product quality. The company had failed to ensure that equipment surfaces in contact with raw materials and APIs maintained specifications and did not alter product quality. While the company responded with corrective actions including equipment servicing, inspection, and replacement, the violations indicated systemic control failures in their manufacturing processes.